Australia markets close in 14 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.6179-0.0368 (-5.62%)
At close: 04:00PM EDT
0.6200 +0.00 (+0.34%)
After hours: 07:49PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 93.31M
Enterprise value 179.28M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.63
Price/book (mrq)63.84
Enterprise value/revenue 1.42
Enterprise value/EBITDA -1.90

Trading information

Stock price history

Beta (5Y monthly) 2.25
52-week change 3-89.77%
S&P500 52-week change 321.83%
52-week high 36.8700
52-week low 30.6110
50-day moving average 30.9191
200-day moving average 32.0308

Share statistics

Avg vol (3-month) 33.93M
Avg vol (10-day) 34.32M
Shares outstanding 5151.01M
Implied shares outstanding 6151.01M
Float 8119.11M
% held by insiders 15.68%
% held by institutions 159.45%
Shares short (28 Mar 2024) 418.8M
Short ratio (28 Mar 2024) 44.14
Short % of float (28 Mar 2024) 417.44%
Short % of shares outstanding (28 Mar 2024) 412.45%
Shares short (prior month 29 Feb 2024) 416.1M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -90.03%
Operating margin (ttm)-61,759.38%

Management effectiveness

Return on assets (ttm)-19.08%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)126.33M
Revenue per share (ttm)0.99
Quarterly revenue growth (yoy)-93.40%
Gross profit (ttm)N/A
EBITDA -101.74M
Net income avi to common (ttm)-113.72M
Diluted EPS (ttm)-0.8900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)127.97M
Total cash per share (mrq)0.85
Total debt (mrq)213.94M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.78
Book value per share (mrq)-0.33

Cash flow statement

Operating cash flow (ttm)-117.35M
Levered free cash flow (ttm)-56.9M